J&J Unit Fights Teva's Bid To Revoke Its Prostate IP
A subsidiary of Johnson & Johnson has fought back against a lawsuit brought by Teva Pharmaceuticals, rejecting claims by the generic drugmaker that the patent for its prostate cancer drug is...To view the full article, register now.
Already a subscriber? Click here to view full article